Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Windlas Biotech Ltd. ( (IN:WINDLAS) ) is now available.
Windlas Biotech’s board has approved the audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2026, with the statutory auditor issuing unmodified opinions on both sets of Ind-AS financial statements. The clean audit opinion reinforces the company’s financial reporting credibility and compliance posture under SEBI’s listing obligations.
The board has also recommended a dividend of Rs. 6.30 per equity share of face value Rs. 5, equivalent to 126%, to be paid within 30 days of shareholder approval at the upcoming AGM. The proposed payout signals management’s confidence in the company’s performance and cash flows, offering a tangible return to investors while potentially enhancing the stock’s appeal in the market.
More about Windlas Biotech Ltd.
Windlas Biotech Limited is an India-based pharmaceutical company listed on BSE and NSE, operating from Dehradun and Gurgaon. The company prepares its financial statements under Indian Accounting Standards and is subject to Securities and Exchange Board of India listing and disclosure regulations, underscoring its role as a regulated player in the domestic capital markets.
Average Trading Volume: 2,558
Technical Sentiment Signal: Sell
Current Market Cap: 16.89B INR
For detailed information about WINDLAS stock, go to TipRanks’ Stock Analysis page.